# Interleukin-2 in Metastatic Melanoma

> **NCT01702896** · PHASE2 · TERMINATED · sponsor: **Western Regional Medical Center** · enrollment: 8 (actual)

## Conditions studied

- Melanoma Metastatic

## Interventions

- **DRUG:** Interleukin-2

## Key facts

- **NCT ID:** NCT01702896
- **Lead sponsor:** Western Regional Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-09
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** PI Decision
- **Last updated:** 2018-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01702896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01702896, "Interleukin-2 in Metastatic Melanoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01702896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*